Get it on Google Play

NeuroSense to present PrimeC Phase 3 data at NEALS meeting

October 29, 2026 11:30 AM EDT Send to a Friend
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced it will present clinical and biomarker findings from its PARADIGM Phase 2b program at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login